OctaplasLG (A) 45-70 mg/ml infusionsvæske, opløsning Danmark - dansk - Lægemiddelstyrelsen (Danish Medicines Agency)

octaplaslg (a) 45-70 mg/ml infusionsvæske, opløsning

octapharma ab - plasmaproteinkoagulationsfaktorer, humane, med plasminhæmmer og von willebrand faktor - infusionsvæske, opløsning - 45-70 mg/ml

Kymriah Den Europæiske Union - dansk - EMA (European Medicines Agency)

kymriah

novartis europharm limited - tisagenlecleucel - precursor b-cell lymphoblastic leukemia-lymphoma; lymphoma, large b-cell, diffuse - andre antineoplastiske midler - kymriah is indicated for the treatment of:• paediatric and young adult patients up to and including 25 years of age with b cell acute lymphoblastic leukaemia (all) that is refractory, in relapse post transplant or in second or later relapse. • adult patients with relapsed or refractory diffuse large b cell lymphoma (dlbcl) after two or more lines of systemic therapy. • adult patients with relapsed or refractory follicular lymphoma (fl) after two or more lines of systemic therapy.

Elzonris Den Europæiske Union - dansk - EMA (European Medicines Agency)

elzonris

stemline therapeutics b.v. - tagraxofusp - lymphoma - antineoplastiske midler - elzonris is indicated as monotherapy for the first-line treatment of adult patients with blastic plasmacytoid dendritic cell neoplasm (bpdcn).

BeneFIX Den Europæiske Union - dansk - EMA (European Medicines Agency)

benefix

pfizer europe ma eeig - nonacog alfa - hæmofili b - antihemorrhagics - behandling og profylakse af blødning hos patienter med hæmofili b (medfødt faktor-ix-mangel).